Horien Biotech (7814) will be listed on the OTC market on July 15th. Alongside the listing announcement, the company recently announced further good news: it has successfully obtained three Class 4 medical device marketing authorizations from the Thai Food and Drug Administration (TFDA), marking another step forward in its expansion into the Southeast Asian market.

 Horien Biotech announced consolidated revenue of NT$14.753 million in June, a year-on-year increase of 209.29%; cumulative revenue for the first half of the year was NT$48.237 million, a year-on-year increase of 55.78%. The company stated that with the increasing penetration rate of its core technologies in regenerative medicine and clinical applications, shipments of its core products are experiencing explosive growth, resulting in strong operational momentum.

 In addition to revenue growth, Horien Biotech has also made new progress in its expansion into the Southeast Asian market. The company stated that it recently received notification from the Thai Food and Drug Administration (TFDA) that its three core products—Horien Extracellular Membrane, Horien Collagen Bone Graft Matrix, and Horien Collagen Matrix—have all passed review and obtained the highest-level Class 4 medical device marketing authorization in Thailand.

 These three approved product technologies all specialize in tissue regeneration and clinical wound repair. The Horien Extracellular Membrane is specifically designed to guide bone and tissue regeneration and is suitable for periodontal defect healing and bone reconstruction. The Horien Collagen Bone Graft Matrix is used to fill periodontal and maxillofacial bone defects, accelerating bone tissue healing and alveolar bone reconstruction. The Horien Collagen Matrix is specifically designed for the care of localized superficial wounds, traumatic injuries, or surgical wounds, providing auxiliary hemostasis when conventional hemostasis is ineffective.

 Horien Biotech pointed out that Thailand is a core market for medical aesthetics and high-end medical care in Southeast Asia. This successful acquisition of the highly challenging Class 4 market access license is not only an international affirmation of Horien Biotechnology's R&D capabilities and superior manufacturing quality, but it will also immediately translate into substantial orders for the Thai market, significantly boosting future revenue.

 Horien Biotechnology General Manager Ho Hsin-Yu stated that the recent strong revenue performance and the acquisition of the high-end medical device certification in Thailand give the company full confidence in promoting Taiwan's regenerative medicine technology to a wider international stage, creating maximum value for shareholders.

Report Link:

Horien Biotech announced good news before its listing! June revenue surged 209%, and it entered the high-end medical device market in Thailand.